Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vonoprazan PK/PD in adolescents with symptomatic GERD
NCT05343364Phase 1Completed
- Sponsor
- Phathom Pharmaceuticals
- Start
- May 2022
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of vonoprazan in gastroesophageal reflux disease (GERD) (2 arms), sponsored by Phathom Pharmaceuticals. Primary endpoints: Maximum Observed Drug Concentration at Steady State at Day 14, Area Under the Plasma Concentration-time Curve During the Dosing Interval tau at Day 14 and 2 more. Started May 2022; status: completed.
02
Drugs
vonoprazan
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT05343364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05343364.